Chronic central melanocortin-4 receptor antagonism and central neuropeptide-Y infusion in rats produce increased adiposity by divergent pathways

Baran, Katherine; Preston, Elaine; Wilks, Donna; Cooney, Gregory J.; Kraegen, Edward W.; Sainsbury, Amanda
January 2002
Diabetes;Jan2002, Vol. 51 Issue 1, p152
Academic Journal
journal article
Increased hypothalamic neuropeptide-Y (NPY) action and disruption of the melanocortin (MC)-4 receptor both result in hyperphagia and obesity. To determine whether similar hormonal and metabolic mechanisms are involved in these two obesity syndromes, we investigated the time course of effects induced by 6-day intracerebroventricular (ICV) infusion of NPY (3.5 nmol/day) or the MC4 receptor antagonist HS014 (4.8 nmol/day) in rats pair-fed with vehicle-infused controls. The weight of white adipose tissue (WAT) deposits was increased after 6-day NPY and HS014 infusion compared with controls, and the increase was significantly greater in HS014- than in NPY-infused rats (retroperitoneal WAT: NPY 0.57 +/- 0.05; HS014 0.80 +/- 0.05; control 0.43 +/- 0.03% body wt, n = 8-13, P < 0.05). Plasma leptin was also increased in both experimental groups (NPY 10.6 +/- 1.9; HS014 4.4 +/- 0.9; control 2.0 +/- 0.1 ng/ml, n = 8-13, P < 0.05 for all comparisons). Basal plasma corticosterone and insulin levels were increased by ICV NPY infusion, whereas HS014-infused rats showed no significant increase in these parameters on any of 1-6 days of infusion. Both NPY and HS014 infusion potentiated intravenous glucose-induced (300 mg/kg) plasma insulin levels, and there was no difference in glycemia among groups. In NPY-infused rats, the plasma free fatty acid levels were decreased and triglyceridemia was increased compared with controls, but these parameters were unchanged in HS014-infused rats. Hepatic triglyceride content was significantly increased by HS014 but not by NPY infusion. Levels of uncoupling protein-1 mRNA in brown adipose tissue were significantly decreased after 6 days of HS014 infusion, similar to the effect of central NPY. Because ICV HS014 induced at least as great an increase in fat mass as ICV NPY and yet had divergent hormonal and metabolic effects, we conclude that MC4 receptor antagonism does not induce obesity solely by regulation of the endogenous NPY-ergic system.


Related Articles

  • New research reveals brain chemical, not unhealthy lifestyle, may be cause of obesity.  // Jet;12/30/96 - 01/06/97, Vol. 91 Issue 7, p33 

    Offers the results of a study conducted on the cause of obesity. Speculation on the role of a brain chemical known as neuropeptide Y or NPY; Comments from Jay Erickson, a Howard Hughes Institute researcher at the University of Washington about the possibility of flawed OB, or fat gene.

  • CORRESPONDENCE.  // British Medical Journal (Clinical Research Edition);6/27/1987, Vol. 294 Issue 6588, p1686 

    Comments on several topics related to medicine in Great Britain. Additional of neuropeptide Y and galanin on the list of peptides possible endocrine causes of obesity; Proposition of a confidential inquiry for the deaths of women from cancer of cervix; Evaluation of the use of hemoglobinometry...

  • Regulation of Gastroduodenal Motility: Acyl Ghrelin, Des-Acyl Ghrelin and Obestatin and Hypothalamic Peptides. Fujimiya, Mineko; Ataka, Koji; Asakawa, Akihiro; Chen, Chih-Yen; Kato, Ikuo; Inui, Akio // Digestion;2012, Vol. 85 Issue 2, p90 

    Real-time measurements for gut motility in conscious rats or mice combined with intracerebroventricular or intravenous injection of peptide agonists or antagonists allow us to understand the regulatory mechanism of gastrointestinal motility. Neuropeptide Y (NPY) in the arcuate nucleus in the...

  • Evidence for a Leptin-Neuropeptide Y Axis for the Regulation of Growth Hormone Secretion in the Rat. Vuagnat, Béatrice A. M.; Pierroz, Dominique D.; Lalaoui, Meriem; Englaro, Piera; Pralong, François P.; Blum, Werner F.; Aubert, Michel L. // Neuroendocrinology;1998, Vol. 67 Issue 5, p291 

    The obese gene (OB) product, leptin, has been shown to exert control on metabolic processes such as food intake and body weight homeostasis, possibly through a neuropeptide Y (NPY) neurotransmission. More recently, leptin has been shown to control several neuroendocrine axes, modulating...

  • The skinny on neurotrophins. Wisse, Brent E; Schwartz, Michael W // Nature Neuroscience;Jul2003, Vol. 6 Issue 7, p655 

    Obesity and its comorbid illnesses are a leading world health concern for which few effective treatments exist. Obesity is increasingly viewed as a disorder of energy homeostasis, a regulatory process that involves hormones such as insulin and leptin that circulate at levels proportionate to...

  • Y2Y4 Receptor Double Knockout Protects Against Obesity Due to a High-Fat Diet or Y1 Receptor Deficiency in Mice. Sainsbury, Amanda; Bergen, Hugo T.; Boey, Dana; Bamming, Darja; Cooney, Gregory J.; Shu Lin; Couzens, Michelle; Stroth, Nikolas; Lee, Nicola J.; Lindner, Diana; Singewald, Nicolas; Karl, Tim; Duffy, Liesl; Enriquez, Ronaldo; Slack, Katy; Sperk, Günther; Herzog, Herbert // Diabetes;Jan2006, Vol. 55 Issue 1, p19 

    Neuropeptide Y receptors are critical regulators of energy homeostasis, but the functional interactions and relative contributions of Y receptors and the environment in this process are unknown. We measured the effects of an ad libitum diet of normal or high-fat food on energy balance in mice...

  • Peripheral-Specific Y2 Receptor Knockdown Protects Mice From High-Fat Diet-Induced Obesity. Shi, Yan-chuan; Lin, Shu; Castillo, Lesley; Aljanova, Aygul; Enriquez, Ronaldo F.; Nguyen, Amy D.; Baldock, Paul A.; Zhang, Lei; Bijker, Martijn S.; Macia, Laurence; Yulyaningsih, Ernie; Zhang, Hui; Lau, Jackie; Sainsbury, Amanda; Herzog, Herbert // Obesity (19307381);Nov2011, Vol. 19 Issue 11, p2137 

    Y2 receptors, particularly those in the brain, have been implicated in neuropeptide Y (NPY)-mediated effects on energy homeostasis and bone mass. Recent evidence also indicates a role for Y2 receptors in peripheral tissues in this process by promoting adipose tissue accretion; however their...

  • Preface[Hot Topic: Medicinal Strategies in the Treatment of Obesity (Guest Editor: Akio Inui)]. Inui, Akio // Current Medicinal Chemistry - Central Nervous System Agents;Sep2003, Vol. 3 Issue 3, p1 

    INTRODUCTION An insidious increase in features of the metabolic syndrome such as obesity, insulin resistance and dyslipidemia, has led to a worldwide epidemic of type 2 diabetes mellitus[1]. This heterogenous disorder accounts for 90-95% of all diabetes and afflicts an estimated 6% of the adult...

  • Fat In, Fat Out. Bedevian, Rima // Plastic Surgery Products;Aug2007, p12 

    The article highlights the results of a study on neuropeptide Y (NPY). The study found that the NPY receptor can prevent the development of fat which can revolutionize plastic surgery and the treatment of diseases that are associated with obesity. The study also shows that stress has a direct...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics